tirzepatide and allodynia GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Tirzepatide Injection for Weight Loss
Description
Slightly nauseous, first week no significant weight loss, but 2nd & 3rd wk 3 lbs each
Allergic reactions, including anaphylaxis have been reported
Long-term, the 20.2% average weight loss seen in SURMOUNT-5 gives you a reasonable benchmark
MOUNJARO (tirzepatide)
Tirzepatide is a dual agonist, or activator, of both GLP-1 and GIP receptors
You must tell your care team about all other medicines you take
